FiercePharma24d
Gilead pulls Trodelvy's approval in bladder cancer after trial flop, FDA discussions
Back in late 2022, GSK pulled the multiple myeloma ADC Blenrep from the U.S. market merely days after announcing a phase 3 trial flop. The British pharma is now aiming to reintroduce the drug in ...
Manila Bulletin28d
National pride: Maguindanaoan woman triumphs in International Qur’an Reading Competition
The NCMF Bureau of Muslim Cultural Affairs (BMCA) organizes the annual Regional and National Qur’an Reading competitions. The male and female champions at the national level are the ones sent to ...
ascopubs.org1mon
Oncology Accelerated Approval Confirmatory Trials: When a Failed Trial Is Not a Failed Drug
2021 Blenrep (belantamab mafodotin-blmf) Adults patients with R/R MM who have received at least four prior therapies including an anti-CD38 monoclonal antibody, a proteasome inhibitor, and an ...
pharmaphorum1mon
GSK's Blenrep hopes take a knock as drug fails trial
GSK has great expectations for its BCMA-directed cancer drug Blenrep, but a failed phase 3 trial in relapsed or refractory multiple myeloma has raised doubts about its prospects – and even the ...
Sharecast8mon
GSK reports more encouraging trial results for Blenrep
GSK unveiled encouraging results from its ‘DREAMM-8’ phase three trial on Thursday, comparing the efficacy of ‘Blenrep’, or belantamab mafodotin, in combination with pomalidomide plus ...